News 2023


Wenger Plattner advises Blue Water Biotech Inc., NASDAQ: BWV

A Wenger Plattner team lead by Oliver Künzler, Partner, Head Corporate/M&A, advised Blue Water Biotech Inc., NASDAQ: BWV, on all Swiss legal aspects with respect to the acquisition of all shares in Proteomedix AG, a private, commercial-stage diagnostics oncology company. The parties also introduced a new name for the combined Company: Onconetix, Inc.

The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix.

The further team consisted of Damian Schai, Partner, IP, Benjamin Dürig, Counsel, Corporate/M&A, Martina Braun, Counsel, Commercial/IP/Data Protection, Cristina Solo de Zaldívar, Counsel, Employment, Valérie Berger, Associate, Corporate/M&A, André S. Berne, Associate, Commercial/Competition, Michèle Fierz, Junior Associate, Corporate/M&A.

More information

> Back to the overview